Merck and AstraZeneca's Cancer Drug Wins 3 New Approvals in Japan

On Monday, two big pharmaceutical companies delivered some good news about one of their projects. Merck (NYSE:MRK) and AstraZeneca (NASDAQ:AZN) announced in separate press releases that their cancer drug Lynparza received approval by Japan's pharmaceutical regulator for the treatment of three types of the disease: prostate, ovarian, and pancreatic.